GAO: FDA is lax in enforcing Phase IV studies for surrogate endpoint drugs
This article was originally published in Scrip
Executive Summary
The US FDA needs to enhance its oversight of accelerated drug approvals based on surrogate endpoints, the Government Accountability Office (GAO) has said in a new report.